Our Capacity Strengthening Hub launches on The Global Health Network today!
The MRC CTU Capacity Strengthening Hub has launched today on The Global Health Network digital platform.
Scotland approves the use of abiraterone in patients with high-risk non-metastatic prostate cancer
NHS Scotland have approved the use of the drug abiraterone to treat patients with prostate cancer at high risk of spreading to other parts of the body.
New podcast episode: Sharing results of clinical trials with participants (part 2)
Tune in to a new episode of the Trial Talk, were we talk to Annabelle South about barriers and challanges of sharing results with trial participants.
STREAM stage 2 study finds all-oral and six-month treatment regimens to be safe and effective
Results from world’s largest clinical trial for Rifampicin-Resistant Tuberculosis show that two new shortened treatment regimens containing the drug bedaquiline are both safe and effective in treating rifampicin resistan…
Innovative clinical trial design and meta-analysis extending beyond the boundaries of single cancer types
Major international clinical trials answering questions of global public health significance
New generation of innovative multi-arm, multi stage platform clinical trials to identify and test new therapeutic treatments in neurodegenerative diseases
Development of methods with direct impact on the design, conduct and analysis of studies
Other Research & Policy
This section will capture projects outside the current QQR themes
(11/11) Next, STAMPEDE2 will open this year to continue the work! This will be a randomised platform trial testing 3 new treatments for metastatic hormone-sensitive #ProstateCancer. STAMPEDE2 is currently in the set-up process, look out for updates👀👇 https://t.co/7JElOeFRcF
(9/11) #STAMPEDEtrial results have driven changes in the standard of care for #ProstateCancer, helping patients live longer. In less than 20 years, it has made progress that may have taken generations with a traditional trial design!⏩ Read more: https://t.co/nfDSc6NMkt